An Exploratory Study to Investigate the Immunomodulatory Activity of Various Dose Levels of Anti Programmed-Death-1 (PD-1) Antibody (BMS-936558) in Subjects With Metastatic Clear Cell Renal Cell Carcinoma (RCC).

For additional information, please contact the BMS oncology clinical trial information
service at 855-216-0126 or email MyCancerStudyConnect@emergingmed.com. Please visit
www.BMSStudyConnect.com for more information on clinical trial participation.

Inclusion Criteria:

- Women and men ≥ 18 years of age.

- Histologic confirmation of renal cell carcinoma with a clear cell component.

- Measurable disease as defined by Response Evaluation Criteria in Solid Tumors
(RECIST).

- Tumor sites that can be accessed for repeat biopsies at acceptable clinical risk.

- Previously treated subjects must have failed at least 1 prior anti-angiogenic agent
and can have a maximum of 3 prior systemic treatments for renal cell cancer.

- Subjects in the treatment naive arm cannot have received prior systemic therapy for
their renal cell carcinoma.

Exclusion Criteria:

- Active or progressing brain metastases.

- Active concomitant.

- Active or history of autoimmune disease.

- Active use of systemic corticosteroids.

- Prior therapy with Cytotoxic T lymphocyte-associated antigen 4 (anti-CTLA4), anti
Programmed death-1 (anti-PD1), anti Programmed death ligand 1 (anti-PD-L1), anti
Programmed death ligand 2 (anti-PD-L2), anti-CD137, anti-CD40, anti-OX40 antibodies.